logo-loader
genedrive PLC

Genedrive PLC - MT-RNR1 ID kit adopted for routine use in Brighton

RNS Number : 5986V
Genedrive PLC
04 December 2023
 

genedrive plc

("genedrive" or the "Company")

 

Royal Sussex County Hospital, Brighton adopts the Genedrive® MT-RNR1 ID Kit for routine use

 Further expansion of hearing loss test into the NHS

 

genedrive plc (AIM: GDR), the point of care Pharmacogenetic testing company, announces the Genedrive® MT-RNR1 ID Kit is now in routine use in the Trevor Mann Baby Unit ("TMBU") at the Royal Sussex County Hospital ("RSCH"), part of University Hospitals Sussex NHS Foundation Trust. This site is the second NHS Trust in the country to be using the Genedrive test for antibiotic induced hearing loss ("AIHL").

 

Each year approximately 450 babies are admitted to the neonatal unit in Brighton. The simple, non-invasive test will be used routinely to guide treatment prescription within the unit from today, 4 December 2023.

 

Inspiration Healthcare and Genedrive have been working closely with the team at the TMBU, providing training and support, to ensure the smooth implementation of the pharmacogenetic point of care test into the neonatal admission process. Every mother and child that comes to RSCH, will now have access to the life-changing test, should it be required.

 

James Cheek, Chief Executive Officer of genedrive plc, said: "Both children and parents in Sussex will have their lives and patient pathways enhanced by having access to this test. It also brings peace of mind and support to clinicians in very stressful circumstances to make the right decision for the patient. On a wider scale, it's great to see how rapid Pharmacogenetics testing is transforming healthcare in time-critical settings, and improving patient safety."

 

For further details, please contact:

 

genedrive plc

+44 (0)161 989 0245

James Cheek: CEO / Russ Shaw: CFO




Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Patrick Birkholm




Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Anna Dunphy

+44 (0)7876 741 001

 

About genedrive plc (http://www.genedriveplc.com) 

 

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need pharmacogenetic platform for the diagnosis of genetic variations. This helps clinicians to quickly access key genetic information that will help them make the right choices over the right medicine or dosage to use for an effective treatment. Based in the UK, the Company is at the forefront of work on Point of Care pharmacogenetics. Pharmacogenetics looks at how your genetics impacts a medicines ability to work for you. Therefore by using pharmacogenetics, medicines can be made safer and more effective. The Company has launched its flagship product, the Genedrive® MT-RNR1 ID Kit, which is a single-use disposable cartridge which circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. This test allows clinicians to make a decision on antibiotic use within 26 minutes, ensuring vital care is delivered with no negative impact on the patient pathway.

 

The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFSAFDLEDSESE
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Riccardo Lowi discusses Genedrive Plc

Riccardo Lowi, analyst at Capital Network on the launch preparation of Genedrive® HCV test with partner Sysmex on track, expect sales to start coming through in CY2018.

on 01/22/2018

4 min read